Metraipolis › archive › dc_97dcb876a394

Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration — Europe PMC PMID:41976308

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41976308
DOI
10.3390/cancers18071085
License (as archived)
solo-consultazione
Archived
2026-11-03T20:50:06.150Z
SHA-256 of the archived text
ae4d0ea6f241c04f3923616eb5f7d8e3cb6237bd4ea126a2bea7c39c1f754d6b
Stable URL of this page
https://metraipolis.com/documento/dc_97dcb876a394

How to cite

Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration — Europe PMC PMID:41976308 — Europe PMC (en), https://europepmc.org/article/MED/41976308 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_97dcb876a394 (Metraipolis archive dc_97dcb876a394, sha256 ae4d0ea6f241c04f3923616eb5f7d8e3cb6237bd4ea126a2bea7c39c1f754d6b)
BibTeX
@misc{dc97dcb876a394,
  title = {Outcomes with Single Tremelimumab Regular Interval Durvalumab (STRIDE) for Unresectable Hepatocellular Carcinoma in the US Veterans Administration — Europe PMC PMID:41976308},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41976308},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_97dcb876a394; sha256 ae4d0ea6f241c04f3923616eb5f7d8e3cb6237bd4ea126a2bea7c39c1f754d6b},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41976308. Agents can read the archived copy with the MCP tool read_document.